Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Abstract Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic stra...

Full description

Bibliographic Details
Main Authors: Lukas Käsmann, Chukwuka Eze, Julian Taugner, Olarn Roengvoraphoj, Maurice Dantes, Nina-Sophie Schmidt-Hegemann, Sanziana Schiopu, Claus Belka, Farkhad Manapov
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Radiation Oncology
Subjects:
Non-small cell lung cancer
Chemoradioimmunotherapy
Multimodal treatment
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13014-020-01595-3

Internet

http://link.springer.com/article/10.1186/s13014-020-01595-3

Similar Items